Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin Plus S-1 vs Docetaxel Plus S-1 in Stage III Gastric Cancer (DRAGON-Adjuvant)
NCT07366528Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin in gastric cancer (GC), sponsored by Ruijin Hospital. Started Dec 2025; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07366528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366528.